Carl Icahn gains ground in Illumina proxy battle.
TL;DR
Activist investor Carl Icahn secured a board seat for one of his three nominees to the board of gene sequencing machine maker Illumina Inc, a partial victory for the investor who is struggling to burnish his credentials following a shortseller attack on his company. Illumina's market value of $30 billion made the fight this year's largest proxy contest to go to a shareholder vote. Its shares closed down 9% at $193.53 on Thursday after Icahn failed in his bid to change the company's management by also ousting Chief Executive Francis deSouza from the board.
- UPDATE 2-Icahn scores partial Illumina win amid pressure to defend investment acumen Yahoo Finance
- Illumina shareholders oust board chair, CEO survives Carl Icahn proxy battle CNBC
- Illumina chair ousted in proxy battle with Carl Icahn Financial Times
- Illumina shareholders vote in one Carl Icahn nominee over chairman FierceBiotech
- Icahn Nominee Elected to Illumina's Board - WSJ The Wall Street Journal
Want the full story? Read the original reporting
Read on Yahoo Finance